CINRYZE Trademark

Trademark Overview

On Thursday, June 21, 2007, a trademark application was filed for CINRYZE with the United States Patent and Trademark Office. The USPTO has given the CINRYZE trademark a serial number of 77212428. The federal status of this trademark filing is REGISTERED AND RENEWED as of Saturday, March 13, 2021. This trademark is owned by Lev Pharmaceuticals, Inc.. The CINRYZE trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for the treatment of conditions associated with inflammatory processes, namely, hereditary angioedema
cinryze

General Information

Serial Number77212428
Word MarkCINRYZE
Filing DateThursday, June 21, 2007
Status800 - REGISTERED AND RENEWED
Status DateSaturday, March 13, 2021
Registration Number3867834
Registration DateTuesday, October 26, 2010
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 10, 2008

Trademark Statements

Goods and Servicespharmaceutical preparations for the treatment of conditions associated with inflammatory processes, namely, hereditary angioedema

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, June 26, 2007
Primary Code005
First Use Anywhere DateThursday, November 20, 2008
First Use In Commerce DateThursday, November 20, 2008

Trademark Owner History

Party NameVIROPHARMA BIOLOGICS LLC
Party Type31 - New Owner After Registration
Legal Entity Type16 - Limited Liability Company
AddressLEXINGTON, MA 02421
Party NameVIROPHARMA BIOLOGICS, INC.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressLEXINGTON, MA 02421
Party NameVIROPHARMA BIOLOGICS, INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressLEXINGTON, MA 02421
Party NameLev Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressExton, PA 19341
Party NameLev Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Saturday, March 13, 2021NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Saturday, March 13, 2021REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Saturday, March 13, 2021REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Saturday, March 6, 2021CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, November 30, 2020TEAS SECTION 8 & 9 RECEIVED
Wednesday, July 22, 2020AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Wednesday, July 1, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, July 1, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, July 1, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, July 1, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, July 1, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, October 26, 2019COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Monday, September 26, 2016NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Monday, September 26, 2016REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Monday, September 26, 2016CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, July 20, 2016TEAS SECTION 8 & 15 RECEIVED
Monday, October 26, 2015COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Thursday, September 3, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, October 26, 2010REGISTERED-PRINCIPAL REGISTER
Thursday, September 23, 2010NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, September 22, 2010LAW OFFICE REGISTRATION REVIEW COMPLETED
Wednesday, September 22, 2010ASSIGNED TO LIE
Wednesday, September 15, 2010ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, September 15, 2010NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 14, 2010STATEMENT OF USE PROCESSING COMPLETE
Thursday, September 2, 2010USE AMENDMENT FILED
Tuesday, September 14, 2010EXTENSION 4 GRANTED
Thursday, September 2, 2010EXTENSION 4 FILED
Thursday, September 2, 2010TEAS EXTENSION RECEIVED
Thursday, September 2, 2010TEAS STATEMENT OF USE RECEIVED
Thursday, March 4, 2010EXTENSION 3 GRANTED
Monday, March 1, 2010EXTENSION 3 FILED
Monday, March 1, 2010TEAS EXTENSION RECEIVED
Tuesday, September 22, 2009EXTENSION 2 GRANTED
Wednesday, September 2, 2009EXTENSION 2 FILED
Tuesday, September 22, 2009CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, September 2, 2009TEAS EXTENSION RECEIVED
Wednesday, July 8, 2009ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Friday, February 27, 2009EXTENSION 1 GRANTED
Friday, February 27, 2009EXTENSION 1 FILED
Friday, February 27, 2009TEAS EXTENSION RECEIVED
Tuesday, December 9, 2008ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, December 9, 2008TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, October 27, 2008ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, October 27, 2008TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, September 2, 2008NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 10, 2008PUBLISHED FOR OPPOSITION
Wednesday, May 21, 2008NOTICE OF PUBLICATION
Friday, May 2, 2008LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, May 2, 2008ASSIGNED TO LIE
Friday, May 2, 2008APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, April 4, 2008TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 3, 2008CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 3, 2008TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, October 3, 2007NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, October 3, 2007NON-FINAL ACTION E-MAILED
Wednesday, October 3, 2007NON-FINAL ACTION WRITTEN
Monday, September 24, 2007ASSIGNED TO EXAMINER
Tuesday, June 26, 2007NEW APPLICATION ENTERED IN TRAM

Related Keywords

cinryze processes namely hereditary angioedema inflammatory associated preparations treatment conditions pharmaceutical